Immuno-activation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapy
| Autor: | C. H. Fox, Hetty Blaak, van R.P. Rij, de F. Wolf, J. M. A. Lange, Hanneke Schuitemaker, van R.M.E. Praag, ten R.J.M. Berge, Suzanne Jurriaans, P. T. A. Schellekens, Marijke T. L. Roos, Jaap Goudsmit, S.L. Yong, Jan M. Prins |
|---|---|
| Přispěvatelé: | Other departments |
| Jazyk: | angličtina |
| Rok vydání: | 1999 |
| Předmět: |
Interleukin 2
Anti-HIV Agents medicine.medical_treatment T cell T-Lymphocytes Immunology Viremia HIV Infections Lymphocyte Activation Virus Replication Muromonab-CD3 medicine Immunology and Allergy Humans In Situ Hybridization Chemotherapy biology business.industry Immunotherapy biology.organism_classification medicine.disease Virology Recombinant Proteins Infectious Diseases medicine.anatomical_structure Lentivirus DNA Viral biology.protein HIV-1 Interleukin-2 RNA Viral Lymph Nodes Antibody business medicine.drug |
| Zdroj: | AIDS (London, England), 13(17), 2405-2410. Lippincott Williams and Wilkins |
| ISSN: | 0269-9370 |
| DOI: | 10.1097/00002030-199912030-00012 |
| Popis: | Background A stable reservoir of latently infected, resting CD4 T cells has been demonstrated in HIV-1-infected patients despite prolonged antiretroviral treatment. This is a major barrier for the eradication of HIV by antiretroviral agents alone. Activation of these cells in the presence of antiretroviral therapy might be a strategy to increase the turnover rate of this reservoir. Methods Three HIV-1-positive patients on potent antiretroviral therapy, in whom plasma viremia had been suppressed to below 5 copies/ml for at least 26 weeks, were treated with a combination of OKT3 (days 1-5) and recombinant human IL-2 (days 2 6). Results The side-effects were fever, headache, nausea, diarrhea, and in one of the patients transient renal failure and seizures. The regimen resulted in profound T cell activation. In one patient plasma HIV-1 RNA transiently increased with a peak at 1500 copies/ml. In the other two patients plasma HIV-1 RNA levels remained below the detection limit, but HIV-1 RNA levels in the lymph nodes increased two- to threefold. All patients developed antibodies against OKT3. Conclusion OKT3/IL-2 resulted in T cell activation and proliferation, and could stimulate HIV replication in patients having achieved prolonged suppression of plasma viremia. OKT3/IL-2 therapy was toxic and rapidly induced antibodies against OKT3. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|